ETX.L - e-Therapeutics plc

LSE - LSE Delayed Price. Currency in GBp

e-Therapeutics plc

17 Blenheim Office Park
Long Hanborough OX29 8LN
United Kingdom
44 1993 880 000

Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Dr. Raymond BarlowCEO & DirectorN/AN/A1969
Mr. Steven MedlicottCFO, Fin. Director & Exec. Director333kN/A1965
Ms. Susan M. StevenCompany Sec.N/AN/A1963
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.


e-Therapeutics plc engages in the discovery and development of drugs through its proprietary platform in network pharmacology and chemical biology. It focuses on the discovery of drugs for cancer. The company's drug candidates include ETS2101, which is in Phase Ib clinical trial for the treatment of hepatocellular and pancreatic cancer. It also develops ETS6103; and ETX1153c products. The company has a research collaboration agreement with C4X Discovery Holdings plc to identify mechanistic insights into Parkinson's Disease. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.

Corporate Governance

e-Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.